Literature DB >> 10666665

Molecular abnormalities of the brain in Down syndrome: relevance to Alzheimer's neurodegeneration.

S M de la Monte1.   

Abstract

Down syndrome is caused by over-expression of genes located within a segment of chromosome 21, termed the Down locus. Down syndrome is associated with developmental abnormalities of the central nervous system that result in mental retardation and age-dependent Alzheimer-type neurodegeneration. Some of the neurodegenerative lesions, including A beta amyloid deposition, apoptotic cell death, and aberrant dendritic arborization, are in part due to constitutively increased expression of genes that encode the amyloid precursor protein, superoxide dismutase I, and S100-beta, and located within the Down locus. However, neurodegeneration in Down syndrome is also associated with aberrant expression of genes that are not linked to the Down locus, including the growth associated protein, GAP-43, nitric oxide synthase 3, neuronal thread protein, and pro-apoptosis genes such as p53, Bax, and interleukin-1 beta-converting enzyme. Increased expression of these non-Down locus genes correlates with proliferation of dystrophic neurites and apoptotic cell death, two important correlates of cognitive impairment in Alzheimer's disease. This article reviews the functional importance of abnormal gene expression in relation to Alzheimer-type neurodegeneration in brains of individuals with Down syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10666665     DOI: 10.1007/978-3-7091-6380-1_1

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  7 in total

1.  Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.

Authors:  S Yamada; T Hongo; S Okada; C Watanabe; Y Fujii; H Hori; M Yazaki; R Hanada; Y Horikoshi
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.

Authors:  Antonella Tramutola; Gilda Pupo; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Chiara Lanzillotta; Diede Brokeaart; Carla Blarzino; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

3.  Enzymatic antioxidant balance and cognitive decline in aging--the EVA study.

Authors:  Claudine Berr; Marie-Jeanne Richard; Véronique Gourlet; Catherine Garrel; Alain Favier
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

4.  Mechanisms of ceramide-mediated neurodegeneration.

Authors:  Ming Tong; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

5.  Overexpression of FABP7 in Down syndrome fetal brains is associated with PKNOX1 gene-dosage imbalance.

Authors:  Ma Francisca Sánchez-Font; Anna Bosch-Comas; Roser Gonzàlez-Duarte; Gemma Marfany
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

Review 6.  Signaling effect of amyloid-beta(42) on the processing of AbetaPP.

Authors:  Massimo Tabaton; Xiongwei Zhu; George Perry; Mark A Smith; Luca Giliberto
Journal:  Exp Neurol       Date:  2009-09-09       Impact factor: 5.330

Review 7.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.